Ayble Health Raises $16M Series A Led by Neon to Scale Virtual GI Care

Ayble Health Raises $16M Series A Led by Neon

Ayble Health, a Boston-based virtual specialty clinic for chronic digestive conditions, has raised a $16 million Series A round led by Neon. The funding closed on September 16, 2026.

Additional participation in the round came from Upfront Ventures, DigiTx, Cleveland Clinic, Accomplice, M13, and Unum Ventures.

What Ayble Health Does

Ayble Health operates a virtual specialty clinic focused on chronic digestive conditions, including IBS, IBD, acid reflux, and SIBO. The company is extending its care model into adjacent autoimmune conditions.

Patients receive unlimited access to a multidisciplinary team of GI-trained clinicians, dietitians, behavioral health specialists, pharmacists, and health coaches. The care model is supported by AI-driven personalization built on one of the largest GI datasets, according to the company.

Ayble reports 16 peer-reviewed studies validating its outcomes.

Leadership and Origin

The company was founded by Sam Jactel, an IBD patient, and is based in Boston.

Go-to-Market and Payer Coverage

Ayble sells to employers, health plans, and health systems. The company is in-network with most commercial insurers covering more than 80 million Americans.

Ayble was also nominated for the 2026 Galien Prize.

Funding Summary

• Round: Series A
• Amount: $16,000,000 USD
• Date: September 16, 2026
• Lead investor: Neon
• Additional investors: Upfront Ventures, DigiTx, Cleveland Clinic, Accomplice, M13, Unum Ventures

Why It Matters

The Series A gives Ayble Health additional capital as it scales a virtual specialty care model for chronic digestive conditions and moves into adjacent autoimmune areas. The company's combination of a multidisciplinary clinical team, AI-driven personalization, and in-network commercial coverage positions it at the intersection of virtual care delivery and chronic condition management — a segment of interest to employers, health plans, and health systems seeking scalable specialty care alternatives.

For acquisition watchers, Ayble's payer relationships, clinical validation claims, and dataset scale are the assets most likely to draw strategic interest from virtual care platforms, benefits navigators, and health systems looking to add GI specialty depth.